Thanh Luan Nguyen

Thanh Luan Nguyen

Auto-generated profile, based on publicly available information

Thanh Luan Nguyen

Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
TNThanh Luan Nguyen
Thanh Luan Nguyen
HDHoang Ngoc Thao Duong
Hoang Ngoc Thao Duong
CTCong Dang Tran
Cong Dang Tran
PPPhuc Tuong Pham
Phuc Tuong Pham
VHVan Hoang Nam Ho
Van Hoang Nam Ho
VDVan Phieu Duong
Van Phieu Duong
Severe community-acquired pneumonia (SCAP) is a leading cause of intensive care unit (ICU) admission and mortality worldwide (1,2). Bacterial SCAP, distinct from viral or fungal infections, often triggers a dysregulated host response with systemic inflammation, endothelial dysfunction, and organ injury (3), providing a rationale for adjunctive immunomodulatory therapies such as corticosteroids (3,4).Corticosteroids have been widely investigated in pneumonia and sepsis because of their potential to attenuate cytokine release, preserve vascular integrity, and limit lung injury (4).Although the latest guidelines suggest or conditionally recommend corticosteroids in SCAP (1,5), evidence from randomized controlled trials (RCTs) remains inconsistent. Some studies demonstrated reductions in treatment failure or mortality (6)(7)(8), while others showed no significant clinical benefit (9,10). These divergent findings likely reflect variability in enrolled populations, causative pathogens, corticosteroid regimens, and study designs (11,12).Emerging data suggest that corticosteroids effects depend on systemic inflammation and treatment protocol (13,14), emphasizing the need for individualized rather than universal use. This paper revisits recent clinical trials of corticosteroids in SCAP, distills key lessons, examines challenges related to heterogeneous etiologies, inflammatory phenotypes, and therapeutic regimens, and outlines implications for current practice and future research.The pathophysiology of SCAP is marked by an excessive and dysregulated host immune response that contributes substantially to lung injury and systemic complications. During the acute phase, pathogen recognition leads to activation of nuclear factor κB (NF-κB) and other transcriptional pathways, with subsequent release of proinflammatory cytokines such as tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 (3,15,16). This hyperinflammatory cascade disrupts alveolar-capillary integrity, increases vascular permeability, and amplifies the risk of acute respiratory distress syndrome (ARDS) and multiorgan dysfunction (17,18).Corticosteroids exert pleiotropic immunomodulatory effects that directly target these mechanisms. By binding to cytoplasmic glucocorticoid receptors, they translocate to the nucleus and suppress transcription of proinflammatory genes while upregulating antiinflammatory mediators (4,15). Beyond cytokine suppression, corticosteroids stabilize endothelial and epithelial barriers, reduce leukocyte recruitment, and limit pulmonary edema (19)(20)(21). Preclinical studies suggest that corticosteroids may influence mitochondrial homeostasis and attenuate secondary tissue injury in non-infectious or in vitro injury models, although evidence in SCAP is lacking (22,23). Moreover, observational and mechanistic studies have linked higher systemic inflammation (e.g., elevated IL-6, CRP) with worse outcomes in pneumonia (15)(16)(17), and randomized trials suggest that the largest clinical gains from adjunctive corticosteroids occur in patients with a pronounced inflammatory response (8,13). These findings support the concept that modulation of the inflammatory milieu is the critical therapeutic target for corticosteroids in bacterial SCAP.Beyond their anti-inflammatory actions, corticosteroids modulate both innate and adaptive immunity by promoting macrophage efferocytosis, enhancing clearance of apoptotic cells, and fostering a shift toward reparative immune phenotypes (24). They also upregulate antiinflammatory mediators such as IL-10 and annexin A1, supporting resolution of inflammation and restoration of tissue homeostasis (25). In parallel, corticosteroids preserve endothelial integrity and regulate neutrophil trafficking, thereby limiting capillary leakage and alveolar injury. These actions indicate that corticosteroids not only suppress inflammation but also promote active disease resolution and tissue repair, providing a robust biological rationale for their use in bacterial SCAP characterized by severe systemic inflammation.Taken together, these biological insights provide the rationale for investigating corticosteroids as an adjunctive therapy in bacterial SCAP. They also show that the net clinical effect is determined not only by the intensity of inflammation but also by the timing, dose, and duration of corticosteroid administration in clinical practice (11,12).Over the last decade, several RCTs have evaluated adjunctive corticosteroids in patients with bacterial SCAP, but the results remain inconsistent (Table 1). The trial by Torres et al. demonstrated that methylprednisolone reduced treatment failure in patients with severe pneumonia and elevated C-reactive protein (CRP >150 mg/L), suggesting benefit in those with a heightened inflammatory response (8). More recently, the CAPE-COD trial reported a significant reduction in 28-day mortality and increased organ support-free days with hydrocortisone in ICU patients with SCAP, reinforcing the potential utility of early corticosteroid therapy (6). Similarly, a multicenter subgroup analysis of the APROCCHSS trial reported a shorter time to clinical stability and fewer complications in patients with SCAP and septic shock who were randomized to hydrocortisone plus fludrocortisone versus placebo (7).In contrast, other RCTs failed to demonstrate clear survival benefit. The ESCAPe trial found no significant effect of methylprednisolone on 60-day mortality or on any of the secondary outcomes (9). This study enrolled predominantly older male veterans, raising concerns about generalizability to broader ICU populations. Likewise, the REMAP-CAP adaptive platform trial screened more than 20,000 patients with pneumonia but ultimately randomized fewer than 1,000 and reporting neutral results for hydrocortisone with respect to mortality (10). Some analyses have underscored the considerable heterogeneity across trials (11,12). Key sources of...

10 November 2025 in Critical Care
Verified
Journal Article
Open access
PDF file
TNThanh Luan Nguyen
Thanh Luan Nguyen
PDPhieu Van Duong
Phieu Van Duong
HDHoang Ngoc Thao Duong
Hoang Ngoc Thao Duong
PPPhuc Tuong Pham
Phuc Tuong Pham
VHVan Hoang Nam Ho
Van Hoang Nam Ho
CTCong Dang Tran
Cong Dang Tran

6 January 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
TNThanh Luan Nguyen
Thanh Luan Nguyen
QLQuang Dai Le
Quang Dai Le
TDTrang Nguyen Hoai Dinh
Trang Nguyen Hoai Dinh
VHVan Hoang Nam Ho
Van Hoang Nam Ho
CTCong Dang Tran
Cong Dang Tran
TBTuyet Phuong Bui
Tuyet Phuong Bui

11 May 2026 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
TNThanh Luan Nguyen
Thanh Luan Nguyen
HDHoang Ngoc Thao Duong
Hoang Ngoc Thao Duong
TNThi Bao Yen Nguyen
Thi Bao Yen Nguyen
QLQuang Dai Le
Quang Dai Le
PHPhan Ngoc An Huynh
Phan Ngoc An Huynh
PDPhieu Van Duong
Phieu Van Duong
Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.

26 June 2026 in Medicine
Verified
Journal Article
Open access
TNThanh Luan Nguyen
Thanh Luan Nguyen
TNThi Bao Yen Nguyen
Thi Bao Yen Nguyen
NNNgoc Nhu Y Nguyen
Ngoc Nhu Y Nguyen
PHPhan Ngoc An Huynh
Phan Ngoc An Huynh
TBTuyet Phuong Bui
Tuyet Phuong Bui
TNTrieu Hoang Kim Ngan
Trieu Hoang Kim Ngan
The association between early magnesium sulfate administration and outcomes in sepsis remains incompletely understood, particularly in relation to differences in systemic immune–inflammatory status. In this retrospective cohort study using Medical Information Mart for Intensive Care IV (version 3.1), adult critically ill patients with sepsis were included. Systemic immune–inflammation index (SII) was calculated from platelet, neutrophil, and lymphocyte counts obtained within a peri-intensive care unit window (6 hours before to 24 hours after intensive care unit admission). Early magnesium administration was defined as intravenous magnesium sulfate initiated within the same window. The primary outcome was 30-day all-cause mortality. Propensity score matching was performed to balance baseline characteristics. Associations were examined overall and across SII quartiles using stratified multivariable Cox proportional hazards models, with nonlinear relationships explored using restricted cubic splines. Among 12,087 patients, 6039 received early intravenous magnesium. After propensity score matching, 3396 matched pairs were analyzed. Early magnesium administration was associated with lower 30-day mortality overall (15.8% vs 18.3%, P = .007). In stratified analyses, adjusted hazard ratios were 0.66 (95% confidence interval: 0.51–0.87), 0.65 (0.49–0.85), 0.75 (0.59–0.94), and 0.85 (0.70–1.04) across quartiles 1 to 4. Restricted cubic spline analyses showed descriptive attenuation at higher SII values ( P for interaction = .208), without evidence of a statistically definitive interaction. Early magnesium administration was associated with lower 30-day mortality in critically ill patients with sepsis. Although formal interaction testing did not reach statistical significance, adjusted hazard ratios showed a descriptive gradient of attenuation across increasing SII quartiles, directionally consistent across sensitivity analyses. These findings are hypothesis-generating and require prospective validation.

27 March 2026 in Emergency and Critical Care Medicine
Verified
Journal Article
Open access
TNThanh Luan Nguyen
Thanh Luan Nguyen
PPPhuc Tuong Pham
Phuc Tuong Pham
VHVan Hoang Nam Ho
Van Hoang Nam Ho